Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists launch deep dive into rare sarcomas to unlock immune secrets

NCT ID NCT03967834

Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is collecting tumor and blood samples from 400 people with rare soft tissue sarcomas to learn how their immune system reacts to the cancer. Researchers will also track patients' health over time to see how the disease progresses. The goal is to find clues that could lead to better treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help doctors better understand rare sarcomas and point toward new immune-based treatments for these cancers.
What could go wrong
This is an observational study, not a treatment trial. It will not directly benefit participants, and the findings may not lead to new therapies for years, if at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2021

Expected to finish

Apr 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years at the time of study entry. 2. Diagnosis of one of the following rare sarcoma subtype, confirmed by RRePS network: * Clear Cell Sarcoma (CCS) * Epithelioid Sarcoma (ES) * Perivascular Epithelioid Cell neoplasm (PEComa) * Desmoplastic Small Round Cell Tumours (DSRCT) * Malignant Solitary Fibrous Tumours (mSFT) * Alveolar Soft Part Sarcoma (ASPS) * Epithelioid Hemangioendothelioma (EH) * Low-Grade Fibromyxoid Sarcoma (LGFS) * Sclerosing Epithelioid Fibrosarcoma (SEF). 3. Localized/locally advanced or metastatic disease. 4. In case of localized disease, treatment must not have been yet initiated before inclusion (except surgical excision). 5. In case of metastatic disease, project of new line of systemic treatment must have been decided before inclusion. 6. Patient followed in the center within a standard of care procedure or clinical trial. 7. Archived tumor specimen at initial diagnosis available (before treatment initiation). 8. Evaluable disease (measurable as per RECIST 1.1) or not. 9. ECOG Performance status 0-3. 10. Patient able to participate and willing to give informed consent prior to performance of any study-related procedures. 11. Patient affiliated to a Social Health Insurance in France. Exclusion Criteria: 1. Diagnosis of all other histotypes of soft tissue sarcoma. 2. Any condition contraindicated with procedures required by the protocol. 3. Known history of positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). 4. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure. 5. Pregnant or breast-feeding woman. 6. Patient who has forfeited his/her freedom by administrative or legal award or who is under guardianship.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alveolar soft part sarcoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alveolar soft part sarcoma clear cell sarcoma desmoplastic small round cell tumor epithelioid hemangioendothelioma epithelioid sarcoma low grade fibromyxoid sarcoma neoplasm with perivascular epithelioid cell differentiation sarcoma soft tissue sarcoma solitary fibrous tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alveolar soft part sarcoma Clear cell sarcoma Desmoplastic small round cell tumor Epithelioid hemangioendothelioma Epithelioid sarcoma Low grade fibromyxoid sarcoma Malignant solitary fibrous tumors Perivascular epithelioid cell neoplasms Sclerosing epithelioid fibrosarcoma Soft tissue sarcoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Antoine Lacassagne

    RECRUITING

    Nice, 06189, France

  • Centre Eugene Marquis

    RECRUITING

    Rennes, France

  • Centre Georges François Leclerc

    NOT_YET_RECRUITING

    Dijon, France

  • Centre Jean Perrin

    RECRUITING

    Clermont-Ferrand, 63011, France

  • Centre Leon Berard

    RECRUITING

    Lyon, 69008, France

  • Centre Oscar Lambret

    RECRUITING

    Lille, 59020, France

  • Chu Besancon - Site Jean Minjoz

    RECRUITING

    Besançon, 25000, France

  • Chu Dupuytren

    RECRUITING

    Limoges, France

  • Chu Poitiers

    RECRUITING

    Poitiers, France

  • Chu de Marseille - Hopital de La Timone

    RECRUITING

    Marseille, France

  • Hôpital Cochin - Site Port-Royal

    RECRUITING

    Paris, France

  • Hôpitaux Universitaires de Strasbourg

    RECRUITING

    Strasbourg, France

  • Institut Bergonié

    RECRUITING

    Bordeaux, France

  • Institut Curie

    RECRUITING

    Paris, France

  • Institut Godinot

    RECRUITING

    Reims, France

  • Institut Gustave Roussy

    WITHDRAWN

    Villejuif, 94805, France

  • Institut Paoli-Calmettes

    WITHDRAWN

    Marseille, 13009, France

  • Institut Universitaire du Cancer Toulouse - Oncopole

    RECRUITING

    Toulouse, France

  • Institut de Cancerologie de L'Ouest - Site Rene Gauducheau

    WITHDRAWN

    Saint-Herblain, 44805, France

  • Institut de Cancerologie de Lorraine

    RECRUITING

    Vandœuvre-lès-Nancy, 54519, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.